Key result
This review discusses the effects of cardiac resynchronization therapy on renal function, the impact of baseline renal function on response, and potential risks in patients with cardiorenal syndrome.
Why the study?
Does cardiac resynchronization therapy improve outcomes or renal function in patients with cardiorenal syndrome?
Does cardiac resynchronization therapy improve outcomes or renal function in patients with cardiorenal syndrome?
This review summarizes the effects of cardiac resynchronization therapy on renal function and the impact of baseline renal function on CRT response in patients with cardiorenal syndrome.
Answers are grounded in this paper and cite their sources.
CRT renal effects in cardiorenal syndrome remain uncertain; leaves open need for randomized trials before clinical adoption.
The cardiorenal syndrome (CRS) is a complex clinical syndrome in which dysfunction of either the heart or the kidneys affects the functioning of the other organ system. Many therapies used in heart failure have further detrimental effects on renal function. Cardiac resynchronization therapy (CRT) is a relatively new form of device therapy that reduces morbidity and mortality in patients with heart failure. This review will discuss the effects of CRT on renal function in patients with CRS, the impact of baseline renal function on response to CRT, and potential risks associated with CRT in this unique population.
No takes yet. Share an insight, caveat, or question.
Davis et al. (2011) conducted a review in Cardiorenal syndrome. Cardiac resynchronization therapy (CRT) was evaluated. This review discusses the effects of cardiac resynchronization therapy on renal function, the impact of baseline renal function on response, and potential risks in patients with cardiorenal syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: